Neurocrine Biosciences Inc (NBIX)
140.71
+0.88
(+0.63%)
USD |
NASDAQ |
May 03, 16:00
140.77
+0.06
(+0.04%)
Pre-Market: 20:00
Neurocrine Biosciences Revenue (Quarterly): 515.30M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 515.30M |
| December 31, 2023 | 515.20M |
| September 30, 2023 | 498.80M |
| June 30, 2023 | 452.70M |
| March 31, 2023 | 420.40M |
| December 31, 2022 | 412.00M |
| September 30, 2022 | 387.90M |
| June 30, 2022 | 378.20M |
| March 31, 2022 | 310.60M |
| December 31, 2021 | 312.00M |
| September 30, 2021 | 296.00M |
| June 30, 2021 | 288.90M |
| March 31, 2021 | 236.60M |
| December 31, 2020 | 247.90M |
| September 30, 2020 | 258.50M |
| June 30, 2020 | 302.40M |
| March 31, 2020 | 237.10M |
| December 31, 2019 | 244.10M |
| September 30, 2019 | 222.10M |
| June 30, 2019 | 183.50M |
| March 31, 2019 | 138.40M |
| December 31, 2018 | 131.45M |
| September 30, 2018 | 151.76M |
| June 30, 2018 | 96.90M |
| March 31, 2018 | 71.09M |
| Date | Value |
|---|---|
| December 31, 2017 | 94.52M |
| September 30, 2017 | 60.77M |
| June 30, 2017 | 6.335M |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | 15.00M |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | 19.77M |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 | |
| December 31, 2013 | 0.73M |
| September 30, 2013 | 0.729M |
| June 30, 2013 | 0.73M |
| March 31, 2013 | 0.73M |
| December 31, 2012 | 21.95M |
| September 30, 2012 | 9.357M |
| June 30, 2012 | 10.57M |
| March 31, 2012 | 11.27M |
| December 31, 2011 | 11.11M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
183.50M
Minimum
Jun 2019
515.30M
Maximum
Mar 2024
336.01M
Average
306.50M
Median
Revenue (Quarterly) Benchmarks
| Globus Medical Inc | 616.53M |
| Inspire Medical Systems Inc | 192.51M |
| AIM ImmunoTech Inc | 0.065M |
| Protalix BioTherapeutics Inc | 10.49M |
| Armata Pharmaceuticals Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 43.40M |
| Total Expenses (Quarterly) | 410.00M |
| EPS Diluted (Quarterly) | 0.42 |
| Enterprise Value | 13.21B |
| Gross Profit Margin (Quarterly) | 98.54% |
| Profit Margin (Quarterly) | 8.42% |
| Earnings Yield | 2.58% |
| Operating Earnings Yield | 3.28% |
| Normalized Earnings Yield | 2.097 |